A Phase IIb, Randomized, Double‐blinded, Placebo‐controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Mild‐Moderate ARDS. The gene discussed is CD24; the disease is acute respiratory distress syndrome.